DDIT3 and diffuse large B-cell lymphoma: In the phase III GOYA study of DLBCL patients who compared G-CHOP (n = 706) and R-CHOP (n = 712) followed out to a median observation of 29 months, Vitolo et al. found no improvement in PFS after treatment with obinutuzumab vs. rituximab plus CHOP (103).